Back to Search
Start Over
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2018 Apr; Vol. 93, pp. 79-88. Date of Electronic Publication: 2018 Mar 20. - Publication Year :
- 2018
-
Abstract
- Background: Adjuvant chemotherapy with S-1 for resected pancreatic cancer demonstrated survival benefits compared with gemcitabine in the JASPAC 01 trial. We investigated the effect of these agents on health-related quality of life (HRQOL) of patients in the JASPAC 01 trial.<br />Methods: Patients with resected pancreatic cancer were randomly assigned to receive gemcitabine (1000 mg/m <superscript>2</superscript> weekly for three of four weeks for up to six cycles) or S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles). HRQOL was assessed using the EuroQol-5D-3L (EQ-5D) questionnaire at baseline, months three and six, and every 6 months thereafter. HRQOL end-points included change in EQ-5D index from baseline, responses to five items in the EQ-5D, and quality-adjusted life months up to 24 months.<br />Results: Of randomised 385 patients, 354 patients were included in HRQOL analysis. Mean change in the EQ-5D index was similar in the S-1 and gemcitabine groups within 6 months from treatment initiation (difference, 0.024; P = 0.112), whereas corresponding mean from 12 to 24 months was better in the S-1 group than in the gemcitabine group (difference, 0.071; P < 0.001). Problems in mobility and pain/discomfort were also less frequent in the S-1 group than in the gemcitabine group in that period. Quality-adjusted life months were longer in the S-1 group than in the gemcitabine group (P < 0.001).<br />Conclusion: Adjuvant chemotherapy with S-1 does not improve HRQOL within 6 months from treatment initiation but does improve HRQOL thereafter and quality-adjusted life months.<br />Clinical Trial Registration Number: UMIN000000655 at UMIN CTR.<br /> (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Subjects :
- Aged
Chemotherapy, Adjuvant
Combined Modality Therapy
Deoxycytidine administration & dosage
Deoxycytidine analogs & derivatives
Drug Combinations
Female
Follow-Up Studies
Humans
Male
Oxonic Acid administration & dosage
Pancreatectomy
Pancreatic Neoplasms pathology
Pancreatic Neoplasms surgery
Prognosis
Survival Rate
Tegafur administration & dosage
Gemcitabine
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Pancreatic Neoplasms drug therapy
Quality of Life
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 93
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 29477795
- Full Text :
- https://doi.org/10.1016/j.ejca.2018.01.081